Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 7/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5348530 | 0.82 | CACNA1B (0.69) | CACNA1BITGB3ITGA2BALDH1A1LMNA | |
| SCHEMBL5355682 | 0.81 | CACNA1B (0.70) | CACNA1BITGB3ITGA2BALDH1A1LMNA | |
| SCHEMBL23692482 | 0.81 | CACNA1B (0.58) | CACNA1BITGB3ITGA2BKLK7KLK5 | |
| SCHEMBL5344515 | 0.80 | CACNA1B (0.83) | CACNA1BITGB3ITGA2BALDH1A1LMNA | |
| SCHEMBL5355478 | 0.80 | CACNA1B (0.83) | CACNA1BITGB3ITGA2BALDH1A1LMNA | |
| SCHEMBL17119843 | 0.80 | CACNA1B (0.50) | CACNA1BITGB3ITGA2BKLK7KLK5 | |
| SCHEMBL23692483 | 0.80 | CACNA1B (0.58) | CACNA1BITGB3ITGA2BALDH1A1LMNA | |
| SCHEMBL18519842 | 0.79 | ITGB3 (0.51) | ITGB3ITGA2BKLK7KLK5CXCR3 | |
| SCHEMBL5362006 | 0.79 | CACNA1B (0.81) | CACNA1BITGB3ITGA2BALDH1A1LMNA | |
| SCHEMBL5344911 | 0.79 | CACNA1B (0.81) | CACNA1BITGB3ITGA2BALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013725-A1 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-01-16 | — | — | US | claimed |
| EP-0997147-A1 | AMINO ACID DERIVATIVES | Ono Pharmaceutical Co., Ltd. (JP) | 2000-05-03 | — | — | EP | claimed |
| US-7166590-B2 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-23 | — | — | US | disclosed |
| US-7166590-B2 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-23 | — | — | US | disclosed |
| US-7166590-B2 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030013725-A1 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-01-16 | — | — | US | disclosed |
| EP-0997147-A1 | AMINO ACID DERIVATIVES | Ono Pharmaceutical Co., Ltd. (JP) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013725-A1 | Amino acid derivatives | CACNA1B, SCN1A, SCN2A | CACNA1B 1/4885ITGB3 3139/4885ITGA2B 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.